A Phase 2 Study of HB0017 in Psoriasis Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

January 30, 2026

Conditions
Psoriasis (PsO)
Interventions
BIOLOGICAL

HB0017

300mg Q12W

BIOLOGICAL

HB0017

300mg Q8W

BIOLOGICAL

HB0017

150mg Q4W

Trial Locations (18)

Unknown

RECRUITING

The First Affiliated Hospital of Bengbu Medical College, Bengbu

RECRUITING

Southern Medical University Dermatology Hospital, Guangzhou

RECRUITING

Xiangya Hospital of Central South University, Changsha

RECRUITING

Wuxi Second People's Hospital, Wuxi

RECRUITING

Jiangsu University Affiliated Hospital, Zhenjiang

RECRUITING

Jilin University Second Hospital, Changchun

RECRUITING

Shanxi Medical University Second Hospital, Taiyuan

RECRUITING

Sichuan Provincial People's Hospital, Chengdu

RECRUITING

Chongqing Traditional Chinese Medicine Hospital, Chongqing

RECRUITING

Hangzhou First People's Hospital, Hangzhou

RECRUITING

The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

RECRUITING

Jiaxing First Hospital, Jiaxing

RECRUITING

Wenzhou Medical University Affiliated First Hospital, Wenzhou

RECRUITING

Guangdong Provincial People's Hospital, Guangzhou

RECRUITING

Ningbo Second Hospital, Ningbo

0531

NOT_YET_RECRUITING

Shandong First Medical University Affiliated Dermatology Hospital, Jinan

RECRUITING

Jining First People's Hospital, Jining

RECRUITING

Xingtai People's Hospital, Xingtai

Sponsors
All Listed Sponsors
lead

Huabo Biopharm Co., Ltd.

INDUSTRY